Bank of New Hampshire Sells 10,228 Shares of DexCom, Inc. $DXCM

Bank of New Hampshire lessened its position in DexCom, Inc. (NASDAQ:DXCM) by 91.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 971 shares of the medical device company’s stock after selling 10,228 shares during the period. Bank of New Hampshire’s holdings in DexCom were worth $64,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Trust Co. of Vermont boosted its stake in shares of DexCom by 14.8% during the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock valued at $74,000 after purchasing an additional 145 shares during the period. CVA Family Office LLC lifted its holdings in DexCom by 48.5% during the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after buying an additional 147 shares during the period. IFP Advisors Inc lifted its stake in shares of DexCom by 24.7% during the 3rd quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after purchasing an additional 178 shares during the last quarter. Personal CFO Solutions LLC lifted its stake in shares of DexCom by 5.0% during the 3rd quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock worth $260,000 after purchasing an additional 185 shares during the last quarter. Finally, Keel Point LLC boosted its position in DexCom by 3.1% during the fourth quarter. Keel Point LLC now owns 6,473 shares of the medical device company’s stock valued at $430,000 after purchasing an additional 193 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Stock Performance

DXCM opened at $72.47 on Friday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The firm has a market capitalization of $27.96 billion, a PE ratio of 30.97, a PEG ratio of 1.13 and a beta of 1.45. The company has a current ratio of 1.95, a quick ratio of 1.64 and a debt-to-equity ratio of 0.42. The firm’s 50-day moving average price is $67.07 and its 200 day moving average price is $67.92.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.09. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a net margin of 19.31% and a return on equity of 33.33%. DexCom’s quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.32 EPS. As a group, sell-side analysts expect that DexCom, Inc. will post 2.58 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on DXCM shares. Barclays reaffirmed an “underweight” rating and issued a $64.00 price target (down from $67.00) on shares of DexCom in a report on Monday, May 18th. BTIG Research reissued a “buy” rating and issued a $85.00 price objective on shares of DexCom in a report on Monday, March 9th. Evercore raised DexCom from an “in-line” rating to an “outperform” rating and set a $90.00 price objective for the company in a report on Tuesday, March 24th. Piper Sandler reissued an “overweight” rating and set a $88.00 target price (up from $75.00) on shares of DexCom in a research note on Monday, June 15th. Finally, Canaccord Genuity Group set a $82.00 target price on DexCom and gave the stock a “buy” rating in a research note on Monday, May 18th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $84.83.

Insider Activity at DexCom

In other news, Director Mark G. Foletta sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $74.13, for a total transaction of $296,520.00. Following the completion of the sale, the director owned 52,852 shares in the company, valued at $3,917,918.76. This trade represents a 7.04% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the sale, the executive vice president owned 106,353 shares in the company, valued at approximately $8,034,969.15. This trade represents a 1.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 46,694 shares of company stock valued at $3,343,977 in the last three months. Company insiders own 0.28% of the company’s stock.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.